Date: 2012-09-10
Type of information: R&D agreement
Compound: LSD1 inhibitors
Company: Oryzon (Spain) Cancer Research UK’s Paterson Institute for Cancer Research (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: acute leukemia
Details: * On September 10, 2012, Oryzon and Cancer Research UK’s Paterson Institute for Cancer Research have entered into a collaboration to further study the potential of Oryzon LSD1 inhibitors in the treatment of acute leukemia. This collaborative research is performed by Dr Tim Somervaille’s group. The collaborative program aims to better understand the mechanism by which LSD1 inhibitors are affecting the diverse molecular types of acute leukaemia and other haematological malignancies and to determine in which disease subtypes these drugs could be more effective.Different in vitro and in vivo models will be used to assess the efficacy of various Oryzon advanced LSD1 inhibitors.
Last May, Oryzon announced the nomination of a preclinical candidate for development that is currently in regulatory safety studies and it is expected to be ready for the first tests in humans in early 2013.
The current collaboration agreement contemplates the possibility that The Christie NHS Foundation Trust - a specialist cancer hospital serving the North West of England - be chosento perform the Phase I/IIA studies planned for next year.
Financial terms:
Latest news:
